Chimeric monoclonal antibodies against VEGFA (hereafter referred to as anti-VEGF) are an established treatment modality for different retinal diseases such as wet AMD4, although repeated treatments (typically monthly intravitreal injections) are required to sustain angiogenic suppression, and the therapy fails in at least 20% of cases16, 17. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.